CHOSA Oncology reported a reduced net loss for 2024, continued R&D focus, and completed a key share issue to fund clinical validation and business development, but faces significant liquidity and partnership risks.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.